RecruitingNot ApplicableNCT06610110

Caffeine, CYPA12 and Resistance Exercise

Influence of CYP1A2 on the Acute Effect of Caffeine Intake on Resistance Exercise


Sponsor

Alberto Pérez-López

Enrollment

60 participants

Start Date

Apr 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Introduction: Several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. However, it remains to be elucidated how CYP1A2 polymorphism influences the acute effects of caffeine on this type of exercise. Objectives: The present study aims to analyze the effects of acute caffeine intake on muscular strength, power, and endurance performance according to CYP1A2 polymorphism in men and women.


Eligibility

Min Age: 18 YearsMax Age: 35 Years

Inclusion Criteria5

  • Age between ≥ 18 and ≤ 35 years.
  • Body mass index (BMI) lower than 25 kg/m².
  • Physically active subjects (≥150 min/week of moderate exercise).
  • Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
  • Participants capable of performing the tests.

Exclusion Criteria7

  • History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
  • Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
  • Body mass index (BMI) ≥ 25 kg/m².
  • Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study.
  • Performing strenuous exercise within 48 hours prior to the tests.
  • Failing to replicate the same food intake on the two experimental days.
  • Consuming caffeine after 6 PM on the day prior to training or testing.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTCaffeine

Acute caffeine intake (3 mg/kg)

DIETARY_SUPPLEMENTPlacebo

Placebo (3 mg/kg maltodextrin)


Locations(2)

Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá

Alcalá de Henares, Madrid, Spain

Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá

Alcalá de Henares, Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06610110


Related Trials